Ascelia Pharma

3,155

SEK

-0,63 %

ACE

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Mindre end 1K følgere

Sammenligne

-0,63%

+8,05%

+4,82%

+43,08%

-2,03%

-24,37%

-83,11%

-80,34%

-81,67%

Ascelia Pharma is a pharmaceutical company. The company specializes in the development of orphan drugs in oncology (cancer). The company is developing various drug candidates, where the greatest use is found in the treatment of cancers that affect the liver and stomach. The company was founded in 2000 and is headquartered in Malmö, Sweden but operates on a global level.

Læs mere

Markedsværdi

306,64 mio. SEK

Aktieomsætning

2,69 mio. SEK

Omsætning

EBIT %

P/E

Udbytteafkast, %

Coverage

Disclaimer

Claus Thestrup

CEO, Sweden

Latest research

Latest analysis report

Released: 21.10.2024

Finanskalender

7.2

2025

Årsrapport '24

7.5

2025

Generalforsamling '25

16.5

2025

Delårsrapport Q1'25

ViserAlle indholdstyper

Videopræsentation7.2.2025, 09.00

Ascelia Pharma, Audiocast with teleconference, Q4'24

Ascelia Pharma

Analytikerkommentar27.12.2024, 07.58

Dagens aktienyheder 27/12: Ascelia Pharma og ExpreS2ion Biotech

Dagens aktienyheder med Ascelia Pharma og ExpreS2ion Biotech

Ascelia Pharma ExpreS2ion Biotech Holding

Pressemeddelelse23.12.2024, 09.02

Ascelia Pharma Patent Granted in China for Second Generation Orviglance

Ascelia Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Dagens aktienyheder 18/12: Scandinavian Medical Solutions, GomSpace og Ascelia Pharma AB

Analytikerkommentar18.12.2024, 08.05 af

Jesper Thomsen

Dagens aktienyheder 18/12: Scandinavian Medical Solutions, GomSpace og Ascelia Pharma AB

Dagens aktienyheder med Scandinavian Medical Solutions, GomSpace og Ascelia Pharma AB

Scandinavian Medical Solutions GomSpace Group Ascelia Pharma

Pressemeddelelse17.12.2024, 14.10

Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025

Ascelia Pharma

Analytikerkommentar3.12.2024, 08.05

Dagens aktienyheder 03/12: ExpreS2ion Biotechnologies og Ascelia Pharma

Dagens aktienyheder med ExpreS2ion Biotechnologies og Ascelia Pharma

Ascelia Pharma ExpreS2ion Biotech Holding

Pressemeddelelse2.12.2024, 15.00

Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting

Ascelia Pharma

Selskabsmeddelelse29.11.2024, 10.40

Change in Number of Shares and Votes in Ascelia Pharma AB

Ascelia Pharma

Selskabsmeddelelse22.11.2024, 20.05

Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program

Ascelia Pharma

Analytikerkommentar14.11.2024, 08.02

Dagens aktienyheder 14/11: ExpreS2ion Biotech, Impero, SKAKO, MapsPeople og Ascelia Pharma

Dagens aktienyheder med ExpreS2ion Biotech, Impero, SKAKO, MapsPeople og Ascelia Pharma

SKAKO MapsPeople Impero ExpreS2ion Biotech Holding Ascelia Pharma

Wrap-Up from Interview with Deputy CEO Julie Waras Brogren

Analytikerkommentar14.11.2024, 07.28 af

Claus Thestrup

Wrap-Up from Interview with Deputy CEO Julie Waras Brogren

Ascelia Pharma

Videopræsentation11.11.2024, 13.00 af

Claus Thestrup

Ascelia Pharma - What happened during Q3?

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 11 November at 2.00 PM. During the third quarter, Ascelia Pharma successfully completed its capital increase, allowing the company to focus on preparations for submitting the NDA for Orviglance and engaging with potential partners. In the last quarter of the year (Q4), Ascelia will receive the complete data package from the Orviglance SPARKLE Phase 3 study. Additionally, they will participate in the annual Radiological Society of North America conference in Chicago from December 1-5, 2024, where they will present abstracts from the SPARKLE study in an oral presentation.

Ascelia Pharma

Pressemeddelelse8.11.2024, 12.31

Analytikerkommentar7.11.2024, 07.31 af

Claus Thestrup

Ascelia Pharma: Full study report from the SPARKLE study and Q3 report

Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE.

Ascelia Pharma

Selskabsmeddelelse7.11.2024, 06.30

Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025

Ascelia Pharma

Pressemeddelelse6.11.2024, 21.40

Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE

Ascelia Pharma

Selskabsmeddelelse30.10.2024, 13.45

Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024

Ascelia Pharma

Analytikerkommentar25.10.2024, 07.17

Dagens aktienyheder 25/10: ExpreS2ion Biotechnologies, Ascelia Pharma og Aktier med Friis

Dagens aktienyheder med ExpreS2ion Biotechnologies, Ascelia Pharma og Aktier med Friis

ExpreS2ion Biotech Holding Ascelia Pharma

Forum opdateringer

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk: Ascelia Pharma er et svensk biotechselskab med fokus på lægemidler til cancer behandlinger. Selskabet udvikler og kommercialiserer lægemidler, der er målrettet mod medicinske behov som endnu ...

17.10.2022, 07.59

by Olivier A. de Goeij

Besøg forummet

Ascelia Pharma

3,155

SEK

-0,63 %

Coverage

Latest research

Finanskalender

Ascelia Pharma, Audiocast with teleconference, Q4'24

Dagens aktienyheder 27/12: Ascelia Pharma og ExpreS2ion Biotech

Ascelia Pharma Patent Granted in China for Second Generation Orviglance

Join Inderes community

Inderes account

Dagens aktienyheder 18/12: Scandinavian Medical Solutions, GomSpace og Ascelia Pharma AB

Ascelia Pharma Announces Acceptance of SPARKLE Phase 3 Data for Presentation at the Society of Abdominal Radiology Congress 2025

Dagens aktienyheder 03/12: ExpreS2ion Biotechnologies og Ascelia Pharma

Ascelia Pharma Presents Orviglance SPARKLE Study Primary Results as Cutting-Edge Research at the 2024 RSNA Annual Meeting

Change in Number of Shares and Votes in Ascelia Pharma AB

Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program

Dagens aktienyheder 14/11: ExpreS2ion Biotech, Impero, SKAKO, MapsPeople og Ascelia Pharma

Wrap-Up from Interview with Deputy CEO Julie Waras Brogren

Ascelia Pharma - What happened during Q3?

Redeye: Ascelia Pharma Q3 Update: Cash and progress

Ascelia Pharma, Audiocast with teleconference, Q3'24

Dagens aktienyheder 07/11: TORM, Gubra, Asetek, Ascelia Pharma, WindowMaster og Columbus

Ascelia Pharma: Full study report from the SPARKLE study and Q3 report

Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025

Ascelia Pharma Announces Completion of Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE

Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 30 October 2024

Dagens aktienyheder 25/10: ExpreS2ion Biotechnologies, Ascelia Pharma og Aktier med Friis

Forum opdateringer